Instrumento Inactivo

Acciones pSivida Corp. Nasdaq

Acciones

Duración

Período

Estilo

PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	09/08/16
PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	14/07/16
PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	02/05/16
PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	28/09/15
PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	14/09/15

Sector

	Varia. 1 de ene.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 mil M
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 mil M
ARGENX SE	+1,69 %	22,15 mil M
BIONTECH SE	-17,37 %	21,02 mil M
GENMAB A/S	-9,30 %	18,15 mil M
WUXI APPTEC CO., LTD.	-41,01 %	16,73 mil M
BEIGENE, LTD.	-14,85 %	16,05 mil M
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 mil M
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 mil M